News from Interphex 2014

Catalent commits to ADCs by upping its stake in Redwood

Loading the player...

Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.

In April 2013, Catalent became the latest contract and development manufacturing organisation (CDMO) to invest in ADCs, acquiring the license to market Redwood’s SMARTag platform as well as a minority stake in the company.

During an exclusive interview at Interphex New York last week, Aileen Ruff - Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent – told Biopharma-Reporter.com the firm was pleased with the collaboration and platform, and would be extending them further.

“For better treatments the right technology can really go a long way and we’re really seeing great results in the data so far with our SMARTag ADC technology,” she said. “We’re really proud with our partnership with Redwood, and the site specific, programmable, ADC conjugation technology that allows for more efficacious ADCs.”

She continued: “The scientific data to date is very, very, compelling in terms of performance and efficacy, and in fact we are going to be increasing our stake in Redwood Bioscience as a result… really showing our commitment to the space and the technology.”

Platform and Customer Base

Ruff did not expand on how much of the California-based company Catalent would now own but did talk to us about how the platform differed from the other options on the market and where demand for Catalent’s biologics services were coming from.

“Within ADCs specifically, the site specificity and the programmable nature of the SMARTag technology is unique, we also have our GPEx cell line development technology and those two work together, so we can actually produce ‘SMARTagged’ antibodies using our GPEx technology.”

This offers “stability, expression level and shortened timeline benefits,” she continued, “so the two combined are really a unique offering to the space.”

Furthermore, whilst Catalent’s clients are generally the smaller biotech firms for its biomanufacturing and cell line development services, Ruff said the SMARTag technology “has relevance and application across a much broader customer base.”

“We are engaging with the larger pharmas as well, and really across the spectrum of all of our offerings, we can provide a solution to all of our customers from the small biotechs to the biggest pharma.”

Related News

Catalent to provide cell lines for at least three Hisun biosimilars

Catalent to provide cell lines for at least three Hisun biosimilars in China

In the last decade, Catalent has earned revenue on nearly half of the NCE (new chemical entity) products approved by the US FDA

Catalent looks to cash in with $872m IPO

Catalent and Australian biomarker firm teams on prostate cancer ADC

Catalent and Australian biomarker firm teams on prostate cancer ADC

Antibodies in development

Merck KGaA is latest bi-curious antibody developer in ADC deal with Sutro

Catalent calls  for closer collaboration

Catalent calls for greater academic and industry collaboration on delivery tech

Pharma's demands from manufacturing partners more complex from the start, say Catalent and DPx

CDMO strategic deals 'the new standard,' say Catalent and DPx, but big and small pharma demands differ

Catalent Contract

Catalent contracted to manufacture Valerion's orphan drug candidates

Post-IPO Catalent turns to internal investments to meet new demands

Post-IPO Catalent turns to internal investments to meet new demands

Takeda will pay $20m, plus milestone payments and royalties, to ImmunoGen. (Image: Incase)

$20m Takeda-ImmunoGen licensing deal for cancer ADCs

Catalent to use GPEx tech to make Amarantus' protein candidate

Catalent to use GPEx cell line tech to make Amarantus' protein candidate

Catalent's biologics manufacturing facility in Madison, Wisconsin

Catalent adds antibody combination tech to its biologics arsenal

Catalent's biologics business grew in FY 2015, despite the firm's overall stagnant sales

Catalent to continue "disproportionate" focus on biologics through M&A and tech deals

Catalent set to expand single-use biologics facility in Wisconsin

Catalent to expand biologics facility to keep up with capacity demand

Image: iStock/BamBamImages

Roche and Catalent team up in $600m conjugation tech deal

Management is looking to increase capacity at Catalent's biologics facility in Madison, Wisconsin

Technology, not capacity, driving Catalent’s biologics strategy

Image: iStock/extender01

Catalent sells rights to ADC candidate and gains development contract

ADC development often trial and error says expert

ADC complexity means CMO investment likely to continue says expert

Catalent enters ADC market

Catalent Gets ADC Tech and Enters Fast-Growing Niche Market

Another day, another ADC investment: SAFC adds ADC capacity

Another day, another ADC investment: SAFC adds commercial-scale capacity

Cytotoxics to lead CMO growth, says F&S report

CMOs to Strengthen on Biopharma's Cytotoxic Demand, Report says

Related Products

See more related products